Generics Call Alcon Glaucoma Drug Obvious As Trial Begins
By Bonnie Eslinger ( March 16, 2021, 6:19 PM GMT) -- Two generic-drug makers seeking to invalidate a glaucoma treatment patent owned by a Novartis AG spinoff started off a London trial Tuesday by saying the treatment would be obvious to anyone knowledgeable about the field....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.